Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.48 |
| ▸ | CTSL | P07711 | 6/20 | 0.48 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27667528 | 1.00 | CTSS (0.48) | CTSSCTSLCTSKGRM5PRMT5 | |
| SCHEMBL28757581 | 0.79 | CTSS (0.47) | CTSSCTSLCTSKGRM5PRMT5 | |
| SCHEMBL28757580 | 0.79 | CTSS (0.47) | CTSSCTSLCTSKGRM5PRMT5 | |
| SCHEMBL28757582 | 0.77 | CTSS (0.52) | CTSSCTSLCTSKGRM5ALOX5 | |
| SCHEMBL5364339 | 0.77 | GRM5 (0.42) | CTSSCTSLCTSKGRM5MGAT2 | |
| SCHEMBL4799869 | 0.77 | CTSS (0.69) | CTSSCTSLCTSK | |
| SCHEMBL3894598 | 0.77 | CTSS (0.59) | CTSSCTSLCTSKGRM5 | |
| SCHEMBL3894605 | 0.77 | CTSS (0.59) | CTSSCTSLCTSKGRM5 | |
| SCHEMBL5352710 | 0.76 | NOTUM (0.48) | CTSSCTSLCTSK | |
| SCHEMBL905724 | 0.73 | HTR2C (0.62) | CTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307095-B2 | Osteoporosis; antiarthritic agents; antidiabetic agents; antiinflammatory agents; Alzheimer's disease; shock; central nervous stsrem disorders; anticancer agents; multiple sclerosis, (S)-2-(Benzooxazol-2-ylamino)-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-propionamide | IRM LLC (BM) | 2007-12-11 | — | — | US | claimed |
| US-20070123523-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2007-05-31 | — | — | US | claimed |
| US-7173051-B2 | Inhibitors of cathepsin S | IRM, LLC (BM) | 2007-02-06 | — | — | US | claimed |
| US-20050049244-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-03-03 | — | — | US | claimed |
| US-20100204200-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2010-08-12 | — | — | US | disclosed |
| US-7732449-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2010-06-08 | — | — | US | disclosed |
| EP-1658267-B1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-10-14 | — | — | EP | disclosed |
| US-20090137570-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| CN-100478331-C | Inhibitors of cathepsin s | IRM LLC (BM) | 2009-04-15 | — | — | CN | disclosed |
| US-7501408-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2009-03-10 | — | — | US | disclosed |
| US-20080108595-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-7314872-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-01-01 | — | — | US | disclosed |
| US-7307095-B2 | Osteoporosis; antiarthritic agents; antidiabetic agents; antiinflammatory agents; Alzheimer's disease; shock; central nervous stsrem disorders; anticancer agents; multiple sclerosis, (S)-2-(Benzooxazol-2-ylamino)-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-propionamide | IRM LLC (BM) | 2007-12-11 | — | — | US | disclosed |
| US-20070123523-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2007-05-31 | — | — | US | disclosed |
| US-7173051-B2 | Inhibitors of cathepsin S | IRM, LLC (BM) | 2007-02-06 | — | — | US | disclosed |
| CN-1871216-A | Inhibitors of cathepsin s | IRM LLC (BM) | 2006-11-29 | — | — | CN | disclosed |
| US-20050113356-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-05-26 | — | — | US | disclosed |
| US-20050049244-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-03-03 | — | — | US | disclosed |
| WO-2004112709-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137570-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSL 11/4885CTSK 9/4885 |
| US-20050049244-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSL 11/4885CTSK 9/4885 |
| US-20080108595-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSL 11/4885CTSK 9/4885 |
| US-20050113356-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSL 11/4885CTSK 9/4885 |
| US-20100204200-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSE, CTSV | CTSS 1/4885CTSL 11/4885CTSK 10/4885 |
| US-20070123523-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSL 11/4885CTSK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.